Indeed, one such molecule, Active DNA-dependent ATPase A inhibitor (ADAADi) targets the ATPase domain of both SMARCAL1 and BRG1 and has been shown to be effective against breast cancer cells lines as well as prostate tumors developed in mouse models (Dutta et al., 2012; Wu et al., 2016; Muthuswami et al., 2019). Here, SMARCA4 is linked to breast carcinoma.